Positive Buy Rating for Actinium Pharmaceuticals Driven by Promising Preclinical Data and Strategic Collaborations

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $4.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including promising new preclinical data for Actinium Pharmaceuticals’ pipeline assets. The recent presentation at the American Association for Cancer Research highlighted the potential of ATNM-400 in prostate cancer treatment, showing significant tumor growth inhibition and extended survival in preclinical models. This is particularly noteworthy for patients with metastatic castration-resistant prostate cancer who have limited options after PSMA-targeted therapies.
Additionally, the data on Actimab-A is compelling, demonstrating its anti-leukemic activity and enhanced tumor growth inhibition when used in combination with other treatments in AML models. The ongoing collaboration with Memorial Sloan Kettering Cancer Center to further develop Actimab-A underscores its potential across the AML treatment continuum. These advancements in their pipeline assets contribute to the positive outlook and justify the Buy rating.